Detection of prothrombin gene polymorphism at position 20209 (PT20209C/T): Pilot study in a black population in the United Kingdom

Dear Sir,

Knowledge of the genetic risk factors underlying venous thrombo-embolism (VTE) in the black population remains sparse (1, 2). The two most common genetic variants that predispose to thrombosis (Factor V Leiden and Prothrombin (PT) 20210G/A) occur predominantly in those of European origin and are rare in other ethnic groups (3). Despite this, venous thrombosis has a worldwide prevalence, suggesting that populations of non-European origin possess previously uncharacterised prothrombotic mutations (2). Warshawsky et al have reported a novel C to T mutation occurring one base pair (bp) upstream from the known PT20210G/A polymorphism in four unrelated African-American patients (4). Three of these patients had a history of venous thrombosis or stroke. The polymorphism was absent in 440 individuals from other US ethnic groups including Caucasians, Hispanics, Asians and Native-Americans. The world population distribution and clinical significance of this novel polymorphism remains unclear. As this polymorphism was restricted to African-Americans (most of whom had experienced thromboembolic events), we hypothesised that it might represent a candidate prothrombotic mutation in the UK black population.

We studied a previously reported group of 125 black subjects (5), 61 with a history of deep vein thrombosis (DVT) (27 male and 34 female, mean age 56.2 years, SD 14.6) and 64 healthy controls (9 male and 55 female, mean age 55 years, SD 14). All subjects were of African (28.8%) or Afro-Caribbean origin (71.2%) and had negative thrombophilia tests including genotyping for FV Leiden and PT20210A and phenotypic studies for activated protein C resistance, antithrombin, protein C, free protein S and lupus anticoagulant. Subjects with hereditary thrombophilia (9.1%) were excluded from the study. The control subjects had no known history of VTE or malignancy. Cases had completed a standard course of anticoagulant treatment for objectively confirmed DVT at least 3 months previously. A panel of 50 healthy Asian Indians and 69 healthy South East Asians were also screened for the presence of this polymorphism. A PCR-RFLP based assay that incorporated an invariant digestion site was developed for detection of the PT20209C/T polymorphism (Fig. 1A).

![Figure 1: PCR-RFLP based assay for detection of the PT20209C/T polymorphism.](image)

A) The terminal exon (exon 14) including the 3’ untranslated region (3’UTR) (hatch box) of the prothrombin gene is amplified by PCR. Presence of the T variant at position 20209 of the prothrombin gene removes a cutting site for Cac8 I. An invariant Cac8 I cutting site acts as a control for complete digestion of the PCR product. Hence, Cac8 I restriction analysis of wild type will produce 3 fragments of 322 bp, 103 bp and 146 bp; homozygotes for prothrombin C20209T will produce 425 bp and 146 bp while C20209T heterozygotes will produce 4 DNA fragments of 425 bp, 322 bp, 103 bp and 146 bp.

B) Agarose gel electrophoresis of PCR products after an overnight digestion with Cac8 I at 37°C. Lanes 1 and 3 represent wild type prothrombin gene; lane 2 heterozygote for prothrombin C20209T; lane 4 uncut PCR product and lane 5 DNA molecular marker φX174-Hae III.

Correspondence to:  
Dr Roopen Arya  
Department of Haematological Medicine  
King's College Hospital  
Denmark Hill, London. SE59RS, UK  
Tel: + 44 207 346 3570, Fax: + 44 207 346 1512  
E-mail: roopen.arya@kcl.ac.uk  
Received September 2, 2004  
Accepted after revision October 28, 2004  
Thromb Haemost 2005; 93: 179-80
Of the 61 black patients, one C/T heterozygote was found (Fig. 1B) whereas all the 64 black controls were of the wild type. A DNA sequence analysis was subsequently performed and confirmed heterozygosity for the C/T polymorphism, 1 bp upstream from the known 20210G/A mutation at position 20209. A review of the medical history of this patient revealed that he was a 79-year-old Jamaican male with prostatic carcinoma and proximal DVT. The C20209T polymorphism was not found in any of the 50 healthy Asian Indians or 69 healthy South East Asians tested.

PT20209C/T is a novel polymorphism previously reported in 4 unrelated African Americans but not in white Americans (4). We have demonstrated a low prevalence (1.6%) of this polymorphism in 61 black subjects with venous thrombosis and an absence of the polymorphism in healthy black controls, Asian Indians and SE Asians. The true prevalence of the PT20209C/T polymorphism cannot be defined in a small case-control study but it would appear to be lower in our study population (heterozygosity 0.8%) compared to African-Americans (heterozygosity 4.9%). Interestingly, in an unpublished study of 503 individuals in the UK (unknown ethnicity) referred for standard thrombophilia tests, only one C/T heterozygote was detected. Thus, it would appear that the frequency of this mutation in the UK population is not high. The clinical significance of the 20209C/T polymorphism among the black population remains unclear and there are as yet insufficient data to suggest a possible prothrombotic role. Whether the PT20209C/T polymorphism is associated with elevated prothrombin levels is unknown but this may be a possibility given its proximity to PT20210G/A. Further research is required to clarify the prevalence and significance of the PT20209C/T in the black population.

Peng Yen Soo1, Raj K. Patel2, Steve Best1, Roopen Arya2, Swee Lay Thein1,2
1Department of Haematological Medicine, Guy’s, King’s and St Thomas’ School of Medicine, King’s College London, London, UK
2Department of Haematological Medicine, King’s College Hospital, London, UK

A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis

Dear Sir,

Serotonin (5-HT), a crucial mediator of platelet activation, is conveyed into the cells through a membrane transporter. There is a 44-bp insertion/deletion polymorphism (long [L] and short [S] allele) in the promoter region of the SLC6A4 gene, coding for the 5-HT transporter. The L allele is associated with higher promoter activity (1), increased 5-HT uptake in platelets (2) and with higher 5-HT plasma levels (3). Recently, three case-control studies described an association of the SLC6A4 polymorphism with coronary heart disease (CHD) and myocardial infarction (4–6). Carotid atherosclerosis (CA) measured by ultrasound correlates with existing CHD and is predictive of cardiac events in individuals without clinically evident disease (7). We consequently investigated the association of the SLC6A4 polymorphism with asymptomatic CA among participants of the Study of Health in Pomerania (SHIP).

For this purpose, a total of 629 subjects aged 45 to 79 years had completed genotyping by PCR and ultrasound investigation of the carotid arteries as previously described (8). CA was defined as presence of atherosclerotic plaques in the extracranial carotids on either side (common, internal, external carotids and carotid bifurcation). Hypertension was defined as a systolic blood pressure (BP) of ≥160 mmHg, a diastolic BP of ≥95 mmHg, or intake of antihypertensives. Smoking was defined as current smoking of at least one cigarette per day (mean daily consumption: 13.4 ± 8.8 cigarettes), diabetes as self-reported physician diagnosis of diabetes, or serum haemoglobin A1C (HbA1C) of >7.0%. Non-fasting blood samples were taken and lipids and HbA1C were determined according to standard procedures. Data were analyzed using ANOVA and logistic regression. Gene-to-